Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
REPL
REPL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
REPL News
FDA Leadership Shakeup May Impact Biotech Stocks
1d ago
stocktwits
REPLIMUNE GROUP STOCK SOARS 21% FOLLOWING REPORT OF TRUMP'S INTENT TO DISMISS FDA HEAD MARTY MAKARY
2d ago
moomoo
FDA's Rejection of Replimune Drug Application Sparks Controversy
4d ago
seekingalpha
FDA Rejects Replimune's Drug Application RP1 Amid Controversy
5d ago
stocktwits
FDA Commissioner Defends Drug Rejections Amid Pressure
5d ago
Newsfilter
FDA Commissioner Makary Defends Drug Rejections Amid Controversy
5d ago
CNBC
Pomerantz Investigates Securities Fraud Claims Against Replimune Group, Inc.
May 01 2026
PRnewswire
Replimune Group Under Investigation for Securities Fraud
Apr 28 2026
Globenewswire
FDA Rejects Replimune's Melanoma Drug RP1 Again
Apr 22 2026
stocktwits
FDA Rejects Replimune's RP1 Drug Candidate Amid Market Capitalization Loss
Apr 22 2026
seekingalpha
Pomerantz LLP Investigates Replimune for Securities Fraud
Apr 21 2026
Globenewswire
REPL Faces Pressure After FDA Issues Second Complete Response Letter
Apr 14 2026
stocktwits
Replimune Faces FDA CRL for RP1 Melanoma Therapy Amid Analyst Downgrades
Apr 13 2026
Newsfilter
Replimune Shares Hit All-Time Low After FDA Rejection
Apr 13 2026
seekingalpha
Trump Threatens 50% Tariff on China Amid Trade Tensions
Apr 13 2026
Fool
Replimune's RP-1 Faces Second FDA Rejection, Shares Plunge
Apr 13 2026
stocktwits
Show More News
